A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors

The anti-ErbB2 antibodies trastuzumab and pertuzumab in combination have recently been approved for the treatment of patients with ErbB2-positive metastatic breast cancer. Pertuzumab, which binds to ErbB2 near the center of domain II, and trastuzumab, which binds to the juxtamembrane region of ErbB2...

Full description

Bibliographic Details
Main Authors: Meng, Y, Zheng, L, Yang, Y, Wang, H, Dong, J, Wang, C, Zhang, Y, Yu, X, Wang, L, Xia, T, Zhang, D, Guo, Y, Li, B
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815051/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815051/

Similar Items